The company's Xavine™ precision immunotherapy platform develops off-the-shelf therapeutics that switch off the rogue immune responses causing autoimmunity, allergies, and food sensitivities, meeting the critical unmet need for antigen-specific therapies that inhibit only disease-causing rogue immune cells. Karma leverages expertise in immunology and lipid nanoparticle engineering to develop tolerogenic vaccines, enabling pharmaceutical businesses to expand their allergy pipelines in the competing markets.